Silverarc Capital Management LLC Buys New Shares in Delcath Systems, Inc. (NASDAQ:DCTH)

Silverarc Capital Management LLC acquired a new stake in Delcath Systems, Inc. (NASDAQ:DCTH) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 155,325 shares of the company’s stock, valued at approximately $1,870,000. Silverarc Capital Management LLC owned about 0.49% of Delcath Systems as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of DCTH. Quantbot Technologies LP purchased a new position in shares of Delcath Systems during the 4th quarter worth approximately $66,000. Barclays PLC purchased a new position in Delcath Systems during the third quarter worth approximately $104,000. Jane Street Group LLC acquired a new stake in Delcath Systems during the 3rd quarter worth approximately $110,000. Private Advisor Group LLC acquired a new position in shares of Delcath Systems during the fourth quarter worth about $153,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Delcath Systems during the fourth quarter valued at approximately $156,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH opened at $11.34 on Tuesday. Delcath Systems, Inc. has a fifty-two week low of $4.87 and a fifty-two week high of $16.97. The business’s fifty day moving average price is $13.04 and its two-hundred day moving average price is $12.33. The stock has a market capitalization of $379.13 million, a price-to-earnings ratio of -8.40 and a beta of 0.85.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The company had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. During the same period in the prior year, the business earned ($0.48) EPS. Research analysts expect that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on DCTH shares. Craig Hallum upped their target price on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday, January 17th. HC Wainwright lifted their target price on Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Delcath Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.75.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.